Anti-CD66b/CEACAM8 Antibody, clone 1L6 ZooMAb^® Rabbit Monoclonal

We are committed to bringing you greener alternative products, which adhere to one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed, and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 1L6 is a ZooMAb^® rabbit recombinant monoclonal antibody that detects CD66b/CEACAM8. It targets an epitope within 15 amino acids from the N-terminal half of the protein.

KLH-conjugated linear peptide corresponding to 15 amino acids from the N-terminal half of human CD66b/CEACAM8.

Quality Control Testing

Evaluated by Western Blotting in human peripheral blood mononuclear cells (PBMC) lysate.

Western Blotting Analysis: A 1:10,000 dilution of this antibody detected CD66b/CEACAM8 in human peripheral blood mononuclear cells (PBMC) lysate.

Tested Applications

Western Blotting Analysis: A 1:10,000 dilution from a representative lot detected CD66b/CEACAM8 in human spleen tissue.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected CD66b/CEACAM8 in Human peripheral blood mononuclear cells (PBMC) cells.

Flow Cytometry Analysis: 0.1 µg from a representative lot detected CD66b/CEACAM8 in human peripheral blood mononuclear cells (PBMC).

Affinity Binding Assay: The binding affinity of this antibody to CD66b/CEACAM8 peptide was at least one thousand-fold (1,000X) higher than that obtained with the non-specific control peptide.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Carcinoembryonic antigen-related cell adhesion molecule 8 (UniProt: P31997; also known as CD67 antigen, CD66b, Carcinoembryonic antigen CGM6, Non-specific cross-reacting antigen NCA-95) is encoded by the CEACAM8 (also known as CGM6) gene (Gene ID: 1088) in human. CEACAM8 belongs to the carcinoembryonic antigen (CEA) family. CEACAM8 is a glycosylphosphatidylinositol (GPI)-anchored protein, consisting of approximately 111 amino acids. It has a single N-terminal Ig-like V-type domain and lacks a transmembrane domain. The extracellular domain of CEACAM8 is responsible for interactions with other molecules, while the GPI anchor determines its localization on the cell membrane. It plays important roles in immune regulation and neutrophil function and predominantly expressed by neutrophils and stored in azurophilic granules. It is also detected in lower levels in other myeloid lineage cells, such as monocytes and eosinophils. Upon neutrophil activation, CEACAM8 is translocated from azurophilic granules to the cell surface through vesicular trafficking. CEACAM8 plays a role in granulocyte recruitment and activation, contributing to the defense against bacterial infections. It is also involved in processes such as adhesion, phagocytosis, and respiratory burst, which are crucial for neutrophil-mediated immune responses. CEACAM8 has been implicated in various inflammatory and infectious diseases. It has been associated with neutrophil-mediated tissue damage and inflammatory bowel disease (IBD). In addition, CEACAM8 is involved in the pathogenesis of sepsis, a life-threatening condition characterized by systemic inflammation in response to infection. Changes in CEACAM8 expression and function may contribute to the dysregulation of immune responses and the development of these diseases. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.